Search results
A discovery made as part of research funded by Retina UK has led to a prestigious award of $2.5 million, enabling scientists to undertake more in-depth investigations and work towards a treatment for a particular type of retinitis pigmentosa.
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
The content on this site will have answered some of your queries about inherited sight loss and associated syndromes, but everyone’s circumstances are different and you may have further questions.
It is important to avoid harming your vision, particularly if you have an inherited sight loss condition.
Our Keynote speaker will be Mr Kanmin Xue. Mr Xue is a Consultant Vitreo-retinal Surgeon at the John Radcliffe Hospital and Wellcome Trust clinician scientist fellow at the University of Oxford where he leads the Retinal Disease and Repair Group.
Dr Graham undertook research into the basic mechanisms of retinal vasculitis, inflammation of the blood vessels in the retina, and is an important cause of poor vision in patients with uveitis, inflammation of the uveal tract.
Hajrah Sarkar is a PhD student whose project is funded by Retina UK.
The project aims to develop a cost effective method of examining the entire ABCA4 gene to look for variations that might cause disease.
Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.
Are you affected by inherited sight loss? We are here to help.
